Skip to content
value.today

Idenix Pharmaceuticals Inc.

Total raised
$5 M
1 round on record
Latest round
$5 M
Apr 2011
First round on record
Apr 2011
Today
Acquired
Acquired by Merck & Co., Inc.

Acquired

Matched to this startup by its exact name; the buyer's report is the source.

Acquisition of Idenix Pharmaceuticals Inc.
AcquiredBuyerAcquisition dateCompletionPriceStakeSource
Idenix Pharmaceuticals, IncMerck & Co., Inc.2014—$3.9 B—Annual report

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Idenix Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2011$5 MNo. 1$2 to $10 million

Idenix Pharmaceuticals Inc.: Raise no. 1, Apr 2011

Investors in this round

1 investor had bought by the notice of Apr 22, 2011: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniella C. Beckman · Executive Officer
  • David N. Standring · Executive Officer
  • Douglas J. Mayers · Executive Officer
  • Maria D. Stahl · Executive Officer
  • Paul J. Fanning · Executive Officer
  • Ronald C. Renaud, Jr. · Executive Officer, Director
  • Anthony E. Rosenberg · Director
  • Charles W. Cramb · Director
  • Denise E. Pollard-Knight · Director
  • Robert E. Pelzer · Director
  • Tamar D. Howson · Director
  • Thomas R. Hodgson · Director
  • Wayne T. Hockmeyer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Maria D. Stahl, Senior Vice President and General Counsel. Newest notice filed Apr 22, 2011. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Idenix Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2011).

    SEC Form D · Apr 2011

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2011

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Idenix Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Idenix Pharmaceuticals Inc.
NameRoleNamed in
Daniella C. BeckmanExecutive officerApr 2011
David N. StandringExecutive officerApr 2011
Douglas J. MayersExecutive officerApr 2011
Maria D. StahlExecutive officerApr 2011
Paul J. FanningExecutive officerApr 2011
Ronald C. Renaud, Jr.Executive officerApr 2011
Anthony E. RosenbergDirectorApr 2011
Charles W. CrambDirectorApr 2011
Denise E. Pollard-KnightDirectorApr 2011
Robert E. PelzerDirectorApr 2011
Ronald C. Renaud, Jr.DirectorApr 2011
Tamar D. HowsonDirectorApr 2011
Thomas R. HodgsonDirectorApr 2011
Wayne T. HockmeyerDirectorApr 2011

Acquired (Jan 1, 2014). Acquired by Merck & Co., Inc..